Introduction {#s1}
============

The diagnosis of Parkinson\'s disease (PD) in live patients is fundamentally clinical, and is based on the presence of its cardinal signs (rest tremor, rigidity, bradykinesia, and postural instability), and the absence of atypical data for idiopathic PD. The final confirmation of the diagnosis is made by post-mortem neuropathological analysis. To date, there are no definitive biomarkers to make an accurate differential diagnosis with other parkinsonian syndromes.

Because the cerebrospinal fluid (CSF) is in close contact with the extracellular space of the brain, it is believed that many of the biochemical modifications in the brain should be reflected in the CSF. Therefore, CSF has been widely investigated in PD and in other parkinsonian syndromes with the aim of acquiring knowledge on the pathogenesis of this disease. This article summarizes the data on analyses performed in the CSF of patients diagnosed with PD compared with controls, with regard to: (1) concentrations of neurotransmitters (mainly monoamines and their metabolites), neuromodulators, and related substances as possible biological markers of the disease itself or its complications; (2) concentrations of endogenous neurotoxins; (3) status of oxidative stress markers or substances which could be related with the induction of oxidative stress or with "neuroprotection" against it; (4) status of inflammation and immunological markers, neurotrophic and growth factors, and (5) concentrations of proteins related with the pathogenesis of PD or other compounds.

The aim of this review is to provide an extensive descriptive overview of studies published on this issue (including references to many reports in the last six decades which have historical interest).

Search strategy
===============

References for this review were identified by searching in PubMed from 1966 until June 20, 2014. The term "*Parkinson\'s disease*" was crossed with "*cerebrospinal fluid*" and "*blood brain barrier*," and the related references were selected. Table [1](#T1){ref-type="table"} summarizes a classification of the diverse types of compounds which have been analyzed in the CSF of PD patients in accordance with the search.

###### 

**Relation and classification of compounds measured in CSF of PD**.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(A\) Neurotransmitters, neuromodulators, and related substances
  Dopamine (DA) metabolites: dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), 3-orthomethylDOPA (3-OMD)Serotonin (5-hydroxytryptamine or 5-HT) metabolites or precursors: 5-hydroxytryptophan (5-HTP), 5-hydroxyindoleacetic acid (5-HIAA), kynurenine, 3-hydroxykynurenineNoradrenalin (norepinephrine or NE) metabolites or precursors: 3-methoxy-4-hydroxy-phenylethylenglycol (MHPG), dopamine-beta-hydroxylase (DBH)Acetylcholine (Ach) and related substances: choline, acetylcholine-esterase (AchE), butiryl-cholin-esterase (BchE)Neurotransmitter amino acids: gamma-amino butyric acid (GABA), glutamate, aspartate, glycineNeuropeptides: substantia P (SP), cholecystokinin-8 (CCK-8), met-enkephalin (MET-ENK), leu-enkephalin (LEU-ENK), dynorphin A(1-8), somatostatin, neuropeptide Y (NPY), beta-endorphin, arginine-vasopressine (AVP), vasoactive intestinal peptide (VIP), delta sleep-inducing peptide (DSIP), alpha-melanocyte-stimulating hormone-like, diazepam-binding inhibitor, neurokinin A, corticotropin-releasing hormone (CRH), adrenocorticotropin hormone (ACTH), beta-lipotropine, angiotensin, chromogranins A and B, secretogranin II, orexin-A/hypocretin-1Other neurotransmitters: endogenous cannabinoids, β-phenylethylamineCyclic nucleotides: cyclic adenosine 3′5′ monophosphate (cAMP), cyclic guanosine 3′5′ monophosphate (cGMP)Biopterin derivatives and other cofactors
  \(B\) Endogenous neurotoxins
  Tetrahydroisoquinolin (TIQ) derivatives: 2-methyl-6,7-dihydroxy1,2,3,4-TIQ (2-MDTIQ), 1-MDTIQ (salsolinol). 1-benzyl-1,2,3,4-TIQβ-carbolinium cations (BC+s)
  \(C\) Oxidative stress markers
  Lipid peroxidation markers: Malonyl-dialdehyde (MDA) (E)-4-hydroxynonenal (HNE) Low density lipoprotein (LDL) oxidation products Schiff bases, conjugated dienes, oxidized proteins, and aldehyde polymersDNA oxidation markers: 8′-hydroxy-2′deoxyguanine (8-OHdG) 8-hydrosyguanosine (8-OHG) 8-OHdG/8-OHG ratioTransition metals and related proteins: iron, ferritin, transferring, copper, cerulopasmin, ferroxidase, manganese, zincOther metals: selenium, chromium, magnesium, calcium, aluminum, silicon, cobalt, tin, lead, barium, bismuth, cadmium, mercury, molibdenum, nichel, antimony, strontium, thallium, vanadium, wolfram, and zirconium
  \(D\) Inflamatory and immunological markers
  Inteleukins (IL)Tumor necrosis alpha (TNF-α)Other: leukotrienes. α-1-antichymotrypsin
  \(E\) Growth and neurotrophic factors
  Brain-derived neurotrophic factor (BDNF)Transforming Growth Factors: TGF-α, TGF-β1, TGF-β2Insulin-like growth factor-1 (IGF-1) and IGF-binding proteins (IGFBPs)Neuroregulins (Epidermal Growth Factor or EGF family)
  \(F\) Proteins involved in the pathogenesis of PD
  Microtubular-Associated Protein *Tau* (MAPT)Alpha-synucleinAmiloyd betaNeurofilament proteinsOther proteins: DJ-1, UCH-L1
  \(G\) Other compounds
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Neurotransmitters, neuromodulators, and related substances
==========================================================

Dopamine metabolites
--------------------

Because the main neurochemical finding in PD is the depletion of dopamine (DA) in the nigroestriatal system (Benito-León et al., [@B23]), it is to be expected that the CSF concentrations of the main metabolites of DA, dihydroxyphenyl-acetyc acid (DOPAC) and homovanillic acid (HVA), should be decreased. Indeed, many classical studies have shown variable degrees of decrease in the CSF HVA levels of PD patients compared with controls (Bernheimer et al., [@B24]; Guldberg et al., [@B107]; Johansson and Roos, [@B140]; Olsson and Roos, [@B239]; Gottfries et al., [@B104]; Curzon et al., [@B61]; van Woert and Bowers, [@B313]; Godwin-Austen et al., [@B101]; Mones et al., [@B218]; Papeschi et al., [@B246]; Pullar et al., [@B263]; Cox et al., [@B54]; Voto Bernales et al., [@B319]; Weiner and Klawans, [@B325]; Granerus et al., [@B105]; Davidson et al., [@B62]; Tabaddor et al., [@B288]; Lovenberg et al., [@B172]; Cunha et al., [@B60]; Mann et al., [@B178]; Cramer et al., [@B58]; Mena et al., [@B200]; Pezzoli et al., [@B254]; Burns et al., [@B38]; Gibson et al., [@B99]; Jolkkonen et al., [@B143]; Liu, [@B168]; Hartikainen et al., [@B113]; Strittmatter and Cramer, [@B284]; Chia et al., [@B44]; Mashige et al., [@B191]; Eldrup et al., [@B76]; Cheng et al., [@B43]; Strittmatter et al., [@B285]; Kanemaru et al., [@B145]; Goldstein et al., [@B102]). Engelborghs et al. ([@B77]) reported normal CSF DA and HVA, and decreased DOPAC levels. González-Quevedo et al. ([@B103]) described normal CSF HVA levels, Espino et al. ([@B80]) found decreased HVA only in advanced but not in early PD, Parkinson Study Group DATATOP Investigators found normal levels in early PD (LeWitt et al., [@B166]). Zubenko et al. ([@B347]) described a non-significant trend toward decreased CSF HVA levels in demented PD patients compared with controls. Tohgi et al. ([@B302]) found correlation of CSF DA and HVA levels with akinesia and freezing of gait.

Although levodopa treatment usually increases CSF HVA levels according to the majority of studies, this is not related with clinical improvement, with some exceptions (Durso et al., [@B73]), and pre-treatment CSF HVA levels does not predict levodopa response (Weiner et al., [@B326]; Chase, [@B42]; Curzon et al., [@B61]; Bertler et al., [@B25]; Casati et al., [@B41]; Cox et al., [@B54]; Mones, [@B217]; Weiner and Klawans, [@B325]; Granerus et al., [@B105]; Davidson et al., [@B62]; Liu, [@B168]; Nishi et al., [@B232]; Strittmatter et al., [@B285]; Antkiewicz-Michaluk et al., [@B12]; Durso et al., [@B72]; Krygowska-Wajs et al., [@B154]), except in one study which described an association between relatively high pre-treatment CSF HVA levels and a better response to levodopa (Gumpert et al., [@B108]). One study failed to show changes in ventricular CSF HVA levels after a single acute administration of levodopa (Moussa et al., [@B223]). On the other hand, dopamine agonists such as piribedil and bromocriptine decreased significantly both the basal level (McLellan et al., [@B199]; Rinne et al., [@B267]) and probenecid-induced accumulations of HVA in CSF (Rinne et al., [@B269], [@B267]), indicating that the drugs reduced the turnover of endogenous dopamine. Amantadine did not change HVA levels (Cox et al., [@B54]). Tetrahydrobiopterin (Dissing et al., [@B68]) and L-threo-3,4-dihydroxyphenylserine (precursor or noraderenalin or norepinephrine --NE) (Maruyama et al., [@B189]) increased CSF HVA levels in PD patients, but to a lesser extent than levodopa.

Friedman et al. (Friedman, [@B91]) reported an HVA/5-HIAA ratio in PD patients who developed levodopa-induced dyskinesias (LID) which was significantly higher than in PD patients under levodopa therapy and in controls, but Lunardi et al. ([@B173]) found similar HVA/DA ratios in patients with and without LID. CSF DA, levodopa, and HVA levels were similar in PD patients treated with levodopa with wearing-off motor fluctuations to those without this complication of levodopa therapy, while CSF 3-ortho-methyldopa (3-OMD) levels were higher in the fluctuating patients (Tohgi et al., [@B294]). CSF DOPAC and HVA were similar in PD patients with and without depression (Kuhn et al., [@B155]), and in patients with major depression with PD than in those without PD (Pålhagen et al., [@B241]). CSF HVA levels were correlated with striatal uptake in PD patients measured with PET imaging with carbon-11-labeled 2β-carbomethoxy-3β-(4-fluorophenyl)-tropane (^11^C-FT) (Ishibashi et al., [@B125]).

Tohgi et al. ([@B299], [@B296]) found a significant increase in tyrosine, and a significant decrease in CSF levodopa, DA, and 3-OMD in PD patients, which was related with levodopa dosage, and described an additional decrease in 3-OMD in subjects treated with tolcapone (Tohgi et al., [@B304]). Other authors reported increased CSF 3-OMD related with levodopa therapy (Antkiewicz-Michaluk et al., [@B12]; Krygowska-Wajs et al., [@B154]). On the other hand, Chia et al. ([@B44]) found normal CSF 3-OMD concentrations. Moser et al. ([@B222]) described increased CSF levodopa/3-OMD ratio in PD patients with hallucinations. Iacono et al. ([@B120]) found similar HVA levels in PD patients with postural instability and gait disorders to PD patients without these symptoms.

Although many of the studies of DA metabolites were performed on patients with different types of parkinsonism, with different degrees of severity, and the fact that many of these studies were made using small sample sizes, there is a general consensus that CSF HVA levels are decreased in untreated PD patients and rise after levodopa therapy starts (decreased HVA may not be present in early stages of PD). It is to be expected that low CSF HVA levels should be a reflection of DA depletion in the nigroestriatal system. However, CSF DA metabolite levels are not useful to distinguish between different parkinsonian syndromes and could be normal in early stages of the disease. To our knowledge, no studies have been published regarding the correlation of CSF DA metabolite levels and brain DA levels, although the observation of a correlation between CSF HVA levels and striatal uptake of DA markers in PET imaging (Ishibashi et al., [@B125]), suggests this correlation.

Serotonin (5-hydroxytryptamine or 5-HT) metabolites
---------------------------------------------------

Several studies have described neuronal loss, and presence of Lewy body in serotonergic raphe nuclei in PD patients (Benito-León et al., [@B23]). Tohgi et al. ([@B300],[@B301], [@B296]) reported a 15--20% reduction of CSF 5-HT, tryptophan (precursor of 5-HT), kynurenine and 3-hydroxykynurenine (metabolites of tryptophan) levels in PD patients. CSF 5-HT levels showed a negative correlation with the severity of bradykinesia, rigidity and freezing of the gait, and decreased after levodopa therapy. This group also found a correlation between CSF 5-HIAA levels and akinesia and freezing of gait (Tohgi et al., [@B302]). In contrast, Engelborghs et al. ([@B77]) described increased 5-HT levels. LeWitt et al. ([@B165]) described increased CSF 3-hydroxykynurenine levels, and Widner et al. ([@B330]) described an increased CSF kynurenine/tryptophan ratio in PD patients.

Several studies have shown reduced CSF levels of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of 5-HT, in PD patients (Guldberg et al., [@B107]; Johansson and Roos, [@B140], [@B141]; Olsson and Roos, [@B239]; Gottfries et al., [@B104]; Chase, [@B42]; Rinne and Sonninen, [@B268]; Rinne et al., [@B270]; Davidson et al., [@B62]; Mayeux et al., [@B195], [@B198], [@B197]; Kostić et al., [@B152]; Tohgi et al., [@B301], [@B296]; Mashige et al., [@B191]; Strittmatter et al., [@B285]; Engelborghs et al., [@B77]). Other authors report normal CSF 5-HIAA levels (Papeschi et al., [@B247], [@B246]; Godwin-Austen et al., [@B101]; Granerus et al., [@B105]; Davidson et al., [@B62]; Tabaddor et al., [@B288]; Cramer et al., [@B58]; Burns et al., [@B38]; Chia et al., [@B44]; González-Quevedo et al., [@B103]; Volicer et al., [@B318]; Fukuda et al., [@B94]). Liu et al. ([@B169]) described lower ventricular CSF 5-HIAA levels in patients with rigid-akinetic PD than in patients with tremoric PD, and a negative correlation between CSF 5-HIAA levels and PD severity.

CSF 5-HIAA levels seem to be unchanged by therapy with levodopa (Godwin-Austen et al., [@B101]; Davidson et al., [@B62]), bromocriptine (Gumpert et al., [@B108]), or piribedil (Gumpert et al., [@B108]), or were found decreased by levodopa therapy (Casati et al., [@B41]). Gumpert et al. ([@B108]) described an association between relatively low pre-treatment CSF 5-HIAA levels with a good response to levodopa, while Davidson et al. ([@B62]) reported this association with higher CSF 5-HIAA levels, and others found no such relation (Granerus et al., [@B105]). Tetrahydrobiopterin increased (Dissing et al., [@B68]), and L-threo-3,4-dihydroxyphenylserine decreased (Maruyama et al., [@B189]) CSF 5-HIAA levels.

Some authors have described decreased CSF 5-HIAA (Mayeux et al., [@B195], [@B198], [@B197]; Mena et al., [@B200]; Kostić et al., [@B152]) and 5-HT levels (Mena et al., [@B200]) in PD patients with depression, while others have described normal CSF 5-HIAA in depressed PD patients (Granerus et al., [@B105]; Kuhn et al., [@B155]), and others still have reported similar CSF 5-HIAA levels in patients with major depression with PD tothose without PD (Pålhagen et al., [@B241]). Moser et al. ([@B222]) described increased CSF 5-HIAA in PD patients with hallucinations. Iacono et al. ([@B120]) found higher CSF 5-HT and 5-HIAA and lower 5-HTP levels in PD patients with postural instability and gait disorders than in PD patients without these symptoms.

Studies on the correlation of CSF 5-HT metabolite levels and brain 5-HT levels are lacking. The majority of studies report results on CSF 5-HIAA levels, with the controversial results based on short series of cohorts of patients with PD or other parkinsonian syndromes. Current data do not lend support to the role of CSF 5-HIAA as an unequivocal marker of depression linked to PD.

Noradrenalin (norepinephrine or NE) metabolites
-----------------------------------------------

Neurons containing NE in the brain, mainly in the dorsal nuclei of vagus nerve, are involved in the degenerative process of PD (Benito-León et al., [@B23]). CSF NE levels have been found normal (Turkka et al., [@B308]; Chia et al., [@B44]; Kuhn et al., [@B155]; Engelborghs et al., [@B77]) or decreased (Martignoni et al., [@B185]; Eldrup et al., [@B76]) in PD patients. CSF levels of 3-methoxy-4-hydroxy-phenylethyleneglycol (MHPG), the main metabolite of NE, have been reported to be normal (Wilk and Mones, [@B332]; Davidson et al., [@B62]; Mann et al., [@B178]; Mena et al., [@B200]; Hartikainen et al., [@B113]; Martignoni et al., [@B185]; Chia et al., [@B44]; González-Quevedo et al., [@B103]; Mashige et al., [@B191]; Kuhn et al., [@B155]; Engelborghs et al., [@B77]) or decreased (Granerus et al., [@B105]) in PD patients. CSF MHPG levels do not increase either after treatment with levodopa (Wilk and Mones, [@B332]; Davidson et al., [@B62]) or with the NE precursor L-Threo-3,4-dihydroxyphenylserine (L-threo-DOPS) (Yamamoto et al., [@B340]; Teelken et al., [@B291]), while L-threo-DOPS increases CSF NE levels (Tohgi et al., [@B303], [@B297]).

Several authors have described a negative correlation between CSF MHPG levels and cognitive functioning (Mann et al., [@B178]) and bradyphrenia (Mayeux et al., [@B196]) in PD patients, and others have described a relationship between CSF NE levels with severity of PD assessed by Hoehn & Yahr staging, akinesia scores, and freezing of the gait (Tohgi et al., [@B302]). Pålhagen et al. reported decreased CSF MHPG levels in patients with major depression with PD compared to those without PD (Pålhagen et al., [@B241]).

CSF activity of dopamine-β-hydroxylase (DBH), an enzyme involved in NE synthesis, has been found decreased in PD patients when compared with controls (Matsui et al., [@B194]; Hurst et al., [@B119]).

The normality of CSF MHPG levels found in nearly all studies with PD or other parkinsonian syndromes indicates that this is not a useful marker of PD. The correlation between CSF MHPG and brain NE is unknown.

Acetylcholine (Ach) and related substances
------------------------------------------

CSF levels of Ach (Duvoisin and Dettbarn, [@B74]; Welch et al., [@B328]; Yamada et al., [@B337]) and its precursor choline (Aquilonius et al., [@B15]; Welch et al., [@B328]; Nasr et al., [@B229]) have been reported to be similar in PD patients to controls with the exception of one study in which lower CSF choline levels were described in PD patients (Manyam et al., [@B182]).

CSF activity of acetylcholine-esterase (AchE), the main enzyme involved in Ach degradation, has been reported to be similar in PD patients and controls (Jolkkonen et al., [@B143]; Ruberg et al., [@B272]; Zubenko et al., [@B347]; Sirviö et al., [@B280]; Yoshinaga et al., [@B343]; Manyam et al., [@B182]; Hartikainen et al., [@B113]), although there are studies which have described increased (Ruberg et al., [@B272]), decreased (Konings et al., [@B149]), or normal activity (Zubenko et al., [@B347]; Sirviö et al., [@B280]) in demented patients, and decreased activity only in those patients with the most severe disease (Hartikainen et al., [@B113]).

CSF activity of butirylcholine-esterase (BchE) have been found to be similar in PD patients and controls (Ruberg et al., [@B272]; Sirviö et al., [@B280]), but increased in demented PD patients in a single study (Ruberg et al., [@B272]). Data on CSF Ach and related substances are scarce and based on short series of patients, and do not permit valid conclusions.

Gamma-amino butyric acid (GABA) and other neurotransmitter amino acids
----------------------------------------------------------------------

CSF GABA levels in PD patients have been found to be decreased, when compared with controls, by many authors (Lakke and Teelken, [@B162]; Manyam et al., [@B183], [@B181]; Kuroda et al., [@B161]; Manyam, [@B179]; Teychenné et al., [@B292]; Kuroda, [@B160]; de Jong et al., [@B64]; Araki et al., [@B16]; Tohgi et al., [@B293]), while others have found this value to be normal (Enna et al., [@B78]; Abbott et al., [@B1]; Bonnet et al., [@B32]; Perschak et al., [@B253]; Mally et al., [@B177]; Engelborghs et al., [@B77]) or even increased (Jiménez-Jiménez et al., [@B137]). Manyam and Tremblay ([@B180]) found reduced CSF free GABA levels and normality of conjugated levels. Abbot et al. (Perschak et al., [@B253]) found decreased CSF GABA levels in PD patients treated with levodopa, but not in "*de novo*" PD patients, while other authors found decreased CSF GABA in untreated PD patients (Manyam, [@B179]; de Jong et al., [@B64]), with CSF GABA normal (de Jong et al., [@B64]; Tohgi et al., [@B293]) or slightly decreased (Manyam, [@B179]) in PD patients under levodopa therapy, suggesting that levodopa increases CSF levels. Teychenné et al. ([@B292]) described low CSF GABA especially in PD patients with poor response to therapy or suffering from "on-off" motor fluctuations.

Normality of CSF glutamate levels has been reported by most investigators (Van Sande et al., [@B312]; Gjessing et al., [@B100]; Lakke and Teelken, [@B162]; Lakke et al., [@B163]; Perschak et al., [@B253]; Espino et al., [@B80]; Jiménez-Jiménez et al., [@B137]; Kuiper et al., [@B158]), although 3 groups described decreased CSF glutamate levels (Gründig and Gerstenbrand, [@B106]; Tohgi et al., [@B293]; Mally et al., [@B177]), while CSF glutamine (the main precursor of glutamate) has been found to be normal (Gjessing et al., [@B100]; Lakke and Teelken, [@B162]; Manyam et al., [@B181]; Jiménez-Jiménez et al., [@B137]) or increased (Mally et al., [@B177]).

CSF aspartate levels have been reported as normal (Lakke and Teelken, [@B162]; Manyam, [@B179]; Araki et al., [@B16]; Perschak et al., [@B253]; Mally et al., [@B177]; Jiménez-Jiménez et al., [@B137]; Engelborghs et al., [@B77]), except in the study by Tohgi et al. ([@B293]) who reported decreased CSF aspartate; CSF asparagine (the main metabolite of aspartate) has been found normal (Lakke and Teelken, [@B162]; Manyam, [@B179]; Araki et al., [@B16]; Perschak et al., [@B253]; Jiménez-Jiménez et al., [@B137]; Mally et al., [@B177]; Engelborghs et al., [@B77]).

The results on CSF glycine levels have been reported as normal by most investigators (Gjessing et al., [@B100]; Perschak et al., [@B253]; Manyam et al., [@B181]; Jiménez-Jiménez et al., [@B137]; Mally et al., [@B177]; Engelborghs et al., [@B77]), although two groups found them increased (Lakke and Teelken, [@B162]; Araki et al., [@B16]; Lakke et al., [@B163]), and another decreased (Tohgi et al., [@B293]). In agreement with Tohgi et al. ([@B293]), our group reported lower glycine levels in untreated PD patients when compared with PD patients under levodopa therapy or with controls (Jiménez-Jiménez et al., [@B137]).

Data regarding other (non-neurotransmitter) amino acids are even more controversial. CSF levels of neutral and basic amino acids have been reported to be both increased (Van Sande et al., [@B312]; Lakke and Teelken, [@B162]; Lakke et al., [@B163]), and decreased (Molina et al., [@B210]). Two groups reported decreased (Molina et al., [@B210]; Engelborghs et al., [@B77]) and another increased CSF levels of taurine (Lakke and Teelken, [@B162]; Araki et al., [@B16]; Lakke et al., [@B163]). Ornithine, citruline, and arginine (implicated in the urea cycle, and the two latter in the synthesis of nitric oxide) have been found to be increased (Van Sande et al., [@B312]; Lakke and Teelken, [@B162]; Lakke et al., [@B163]), normal (Kuiper et al., [@B158]), or decreased (Molina et al., [@B210]). Another group described increased CSF levels of total homocysteine but normal ones of free homocysteine in PD patients (Isobe et al., [@B128]), with an additional increase after treatment with levodopa, while total methionine levels decreased after this therapy (Isobe et al., [@B126]).

In general, the results on CSF amino acid levels in PD patients are inconclusive, because they might be influenced by selection of study subjects, sample size, lack of adequate matching between cases and controls in many studies, differences in antiparkinsonian therapy, and differences in study techniques, storage and handling of the samples (Jiménez-Jiménez et al., [@B137]; Molina et al., [@B210]).

Neuropeptides
-------------

Neuropeptides modulate neuronal communication by acting on cell surface receptors. Many of them are co-released with classical neurotransmitters. There have been reports of a number of changes in the concentrations of several neuropeptides in PD brain, which are mainly significant decreases in (Jiménez-Jiménez, [@B139]): (a) met-enkephalin (MET-ENK), substantia P (SP), and cholecystokinine 8 (CCK-8) in the substantia nigra; (b) MET-ENK and leu-enkephalin (LEU-ENK) in the putamen and globus pallidus; (c) MET-ENK in the ventral tegmental area; (d) SP, somatostatin and neurotensin in the neocortex, and (e) somatostatin and neurotensin in the hippocampus. It is likely that many of these changes are related with dopaminergic deficit, and the only clear relationship between a neuropeptide and a clinical feature of PD is that of somatostatin with the presence of cognitive impairment (Jiménez-Jiménez, [@B139]). Table [2](#T2){ref-type="table"} summarizes the findings of classical studies on CSF neuropeptide levels in PD patients. Most of these studies enrolled limited series of patients.

###### 

**Alterations in CSF neuropeptide levels in PD patients compared with controls**.

  **Neuropeptide**                            **References**                     **PD patients/ Controls**   **Cerebrospinal fluid levels**
  ------------------------------------------- ---------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------
  Substantia P (SP)                           Pezzoli et al., [@B254]            12/10                       Increased 5-fold
                                              Cramer et al., [@B57]              15/9                        Normal
                                              Cramer et al., [@B55]              23/9                        Decreased by 30% (controls were essential tremor patients)
  Cholecystokinin-8 (CCK-8)                   Lotstra et al., [@B171]            20/68                       Decreased by 50%
  Met-enkephalin (MET-ENK)                    Pezzoli et al., [@B254]            12/10                       Increased 3-fold in PD patients with slight or moderate disability (*n* = 6)
                                              Yaksh et al., [@B336]              8/9                         Decreased by 37%
                                              Baronti et al., [@B20]             16/19                       Decreased by 31.7%
  Leu-enkephalin (LEU-ENK)                    Liu, [@B168]                       22/19                       Increased by 122% in untreated PD patients without further modification by levodopa therapy
  Dynorphin A(1-8)                            Baronti et al., [@B20]             16/19                       Normal
  Somatostatin                                Jolkkonen et al., [@B143]          35/19                       Decreased by 22% (*p* \< 0.01), especially in demented patients
                                              Strittmatter and Cramer, [@B284]   38/12                       Decreased by 27.5% (*p* \< 0.01)
                                              Strittmatter et al., [@B285]       35/11                       Decreased *p* \< 0.05, similar in untreated vs. treatment with levodopa
                                              Cramer et al., [@B57]              15/9                        Decreased by 39%
                                              Dupont et al., [@B71]              39/29                       Decreased by 40%
                                              Christensen et al., [@B45]         48/32                       Decreased by 40%
                                              Cramer et al., [@B59]              50/6                        Decreased by 34%(controls were patients with essential tremor)
                                              Masson et al., [@B192]             35/11                       Decreased (*p* \< 0.02), especially in untreated patients and in those with more severe disease
                                              Jost et al., [@B144]               68/6                        Decreased by 28%
                                              Hartikainen et al., [@B113]        35/34                       Normal
                                              Volicer et al., [@B317]            10/9                        Normal
                                              Beal et al., [@B21]                6/84                        Normal
                                              Poewe et al., [@B258]              22/11                       Normal in PD patients with dementia (*n* = 11) and without dementia (*n* = 11)
                                              Espino et al., [@B81]              23/26                       Increased by 47%, especially in demented patients
  Neuropeptide Y (NPY)                        Martignoni et al., [@B185]         10/20                       Decreased by 31%
                                              Yaksh et al., [@B336]              8/9                         Normal
  Beta-endorphin                              Nappi et al., [@B228]              24/15                       Decreased (*p* \< 0.005) both in 14 untreated and 10 treated PD patients
                                              Jolkkonen et al., [@B142]          36/35                       Normal
  Arginine-vasopressine (AVP)                 Sundquist et al., [@B287]          11/21                       Decreased by 68%
                                              Olsson et al., [@B238]             12/32 OND                   Decreased by 71%
  Vasoactive intestinal peptide (VIP)         Sharpless et al., [@B275]          19/12                       Normal
  Delta sleep-inducing peptide (DSIP)         Ernst et al., [@B79]               9/20                        Decreased by 28.7% (Ferrero et al., [@B84])
  Alpha-melanocyte-stimulating hormone-like   Rainero et al., [@B266]            9/12                        Increased by 2-fold
  Diazepam-binding inhibitor                  Ferrero et al., [@B84]             25/82                       Increased by 42.5% (80% in depressed PD patients and normal in non-depressed PD patients
                                              Ferrarese et al., [@B83]           28/10                       Decreased by 50% in PDD (*n* = 14), normal in PDND (*n* = 14)
  Neurokinin A                                Galard et al., [@B97]              12/11                       Decreased by 24%
  Corticotropin-releasing hormone (CRH)       Suemaru et al., [@B286]            10/5                        Normal
  ACTH                                        Nappi et al., [@B228]              24/15                       Normal
  Beta-lipotropine                            Nappi et al., [@B228]              24/15                       Normal
  Angiotensin converting enzyme (ECA)         Konings et al., [@B148]            88 PDND/18 PDD/20           Increased in PDND patients under levodopa therapy (*p* \< 0.05). Normal in untreated PDND and in PDD
                                              Zubenko et al., [@B348]            10 PDD/30                   Decreased by 27% in demented PD patients
                                              Zubenko et al., [@B347]            15/10                       Decreased by 24%
  Chromogranin A and B and secretogranin II   Eder et al., [@B75]                8/29                        Normal

OND, other neurological diseases; PDD, Parkinson\'s disease demented; PDND, Parkinson\'s disease non-demented.

In recent years, there has been increased interest in the possible role of orexin-A/hypocretin-1, a neuropeptide hormone implicated in the pathogenesis of narcolepsia, on the development of excessive daytime sleepiness in PD patients. Since the first report by Drouot et al. ([@B70]), who described decreased ventricular CSF orexin levels in PD patients, which were related with the severity of the disease, other authors have confirmed decreased CSF orexin in PD (Fronczek et al., [@B92]; Asai et al., [@B17]) and in other neurodegenerative parkinsonisms (Yasui et al., [@B342]), and the relation of CSF orexin with severity of PD (Asai et al., [@B17]), and with the presence of sleep attacks (Asai et al., [@B17]). In contrast, Compta et al. ([@B50]) found no significant differences in CSF orexin levels between demented PD patients, non-demented PD patients, and healthy controls, and found no relation between CSF orexine and Epworth sleepiness scale or Mini-Mental State Examination. Drouot et al. ([@B69]) found a lack of association between low ventricular CSF orexin and sleepiness in PD, and a relation between high levels of orexin-A in PD associated with loss of REM muscle atonia (Bridoux et al., [@B36]), while Wienecke et al. ([@B331]) reported association between low CSF orexin levels and sleepiness in PD. Finally, Pålhagen et al. ([@B241]) described similar CSF orexin levels in patients with major depression with or without concomitant PD. The results regarding orexin A are controversial, and await confirmation.

Other neurotransmitters
-----------------------

Pisani et al. ([@B256], [@B257]) found increased CSF levels of the endogenous cannabinoid anandamide in untreated PD patients, which were unrelated to the severity of the disease (Pisani et al., [@B256]) and reversed by chronic dopaminergic replacement (Pisani et al., [@B257]). Zhou et al. ([@B346]) found decreased CSF β-phenylethylamine (PEA) levels in PD patients which were correlated negatively with Hoehn & Yahr stage.

Cyclic nucleotides
------------------

These compounds act as intracellular second messengers of neurotransmitters or other compounds such as nitric oxide (NO). The most important are cyclic adenosine 3′5′ monophosphate (cAMP) and cyclic guanosine 3′5′ monophosphate (cGMP). Belmaker et al. ([@B22]) reported a 40--50% decrease of CSF cAMP and an 80--90% decrease of CSF cGMP levels in PD patients who were not related with levodopa therapy. Decreased CSF cAMP levels in PD have also been reported in another study (Volicer et al., [@B317]), while others found this value to be normal (Cramer et al., [@B56], [@B58]; Covicković-Sternić et al., [@B53]; Oeckl et al., [@B235]), both in PD patients with and without dementia (Oeckl et al., [@B235]). Four further studies described normal CSF cGMP levels (Volicer et al., [@B317]; Covicković-Sternić et al., [@B53]; Ikeda et al., [@B121]; Oeckl et al., [@B235]), while another found a non-significant trend toward higher CSF cGMP levels in PD patients when compared with controls and higher levels in levodopa-treated PD patients compared with those without levodopa treatment (Navarro et al., [@B230]).

Biopterin derivatives and other cofactors
-----------------------------------------

Biopterins act as cofactors for aromatic amino acid hydroxylases, which produce a number of neurotransmitters including DA, NE, epinepherine, and 5-HT and are also required for the production of NO. CSF levels of neopterin and biopterin have been found decreased in PD patients by several groups, especially in those with early-onset PD (Fujishiro et al., [@B93]; Furukawa et al., [@B96]), and in carriers of the *PARK8* mutation (Koshiba et al., [@B151]), which was negatively correlated with duration of illness in those patients with akinetic-rigid PD (Furukawa et al., [@B95]). In contrast, another group found increased CSF neopterin in PD (Widner et al., [@B330]).

CSF concentration of hydroxylase cofactor, predominantly composed of tetrahydrobiopterin (BH~4~), has also been found decreased (Williams et al., [@B334],[@B333]).

Thiamine is an essential cofactor for several important enzymes involved in brain oxidative metabolism. Our group found normal CSF levels of thiamine-diphosphate, thiamine-monophosphate, free thiamine, and total thiamine in PD patients (Jiménez-Jiménez et al., [@B135]).

Endogenous neurotoxins
======================

One of the classical etiological hypotheses of PD is related with the presence of endogenous substances which share structural similarities with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces a parkinsonism resembling PD.

Moser et al. (Moser and Kömpf, [@B220]; Moser et al., [@B221]) identified two tetrahydroisoquinolin (TIQ) derivatives in the CSF of PD patients, but not in healthy controls, 2-methyl and 1-methyl-6,7-dihydroxy1,2,3,4-TIQ (2-MDTIQ and 1-MDTIQ or salsolinol). This group described a relation between high salsolinol levels and the presence of visual hallucinations (Moser et al., [@B222]), and reported an increased HVA/3OMD ratio in PD patients in which 2-MDTIQ was detected when compared with those PD in which it was not detectable.

CSF salsolinol levels have been reported to be increased in PD patients compared with controls by other groups (Maruyama et al., [@B187]; Antkiewicz-Michaluk et al., [@B12]; Krygowska-Wajs et al., [@B154]; Naoi and Maruyama, [@B227]), especially in demented PD patients (Antkiewicz-Michaluk et al., [@B12]), and in those patients with more severe parkinsonism (Krygowska-Wajs et al., [@B154]), although other authors have described a trend toward decrease in CSF salsolinol levels with the progression of the disease (Maruyama et al., [@B188]). In contrast, another group reported similar CSF salsolinol (Müller et al., [@B225],[@B226]), but higher levels of harman and norharman β-carbolines (structural analogs of MPTP as well) in PD patients than in controls (Kuhn et al., [@B156]). CSF levels of 1-benzyl-1,2,3,4-TIQ have also been found by another group to be increased (Kotake et al., [@B153]).

Matsubara et al. ([@B193]) measured β-carbolinium cations (BC+s) in the lumbar CSF of 22 PD patients and 11 age-matched controls, and found the 2,9-dimethylnorharmanium cation (2,9-Me2NH+) in 12 PD patients but not in controls. This group described decreased activity of nicotinamide N-methyltranserase (NNMT), an enzyme that catalyzes the N-methylation of nicotinamide and other pyridines in the CSF of younger PD patients compared with younger controls, and a trend toward decrease with aging in PD patients (Aoyama et al., [@B14]).

The results of studies on neurotoxins related with the risk for PD are based on small series and are not conclusive.

Oxidative stress markers
========================

Because there is much evidence on the contribution of oxidative stress in the pathogenesis of PD (Figure [1](#F1){ref-type="fig"}) (Alonso-Navarro et al., [@B8]), the measurement of oxidative stress markers and substances related with oxidative and defense against oxidative phenomena in the CSF of PD patients is useful. Data regarding lipid peroxidation markers are controversial, while DNA oxidation markers have been found to be increased (Table [3](#T3){ref-type="table"}).

![**Pathogenical mechanisms proposed for Parkinson\'s disease (modified from Alonso-Navarro et al., [@B8])**.](fncel-08-00369-g0001){#F1}

###### 

**Alterations in the CSF levels of oxidative stress markers and substances related with oxidative stress in PD patients compared with controls**.

                                                                                                                              **References**                    **PD/Controls**           **Cerebrospinal fluid levels**
  ----------------------------------------------- --------------------------------------------------------------------------- --------------------------------- ------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Lipid peroxidation markers                      Malonyl-dialdehyde (MDA)                                                    Ilić et al., [@B123]              31/16                     Increased (*p* \< 0.001)
                                                                                                                              Ilic et al., [@B122]              33/16                     Increased (*p* \< 0.001)
                                                                                                                              Shukla et al., [@B278]            21/20                     Normal
                                                  (E)-4-hydroxynonenal (HNE)                                                  Selley, [@B274]                   10/10                     Increased 4-fold
                                                  Low density lipoprotein (LDL) oxidation products                            Buhmann et al., [@B37]            70/60 OND/31 HC           Increased 3-fold with --SH decreased 1.5-fold
                                                  Schiff bases, conjugated dienes, oxidized proteins, and aldehyde polymers   Boll et al., [@B30]               22/41                     Increased 1,5 fold (Isobe et al., [@B127])
  DNA oxidation markers                           8\'-hydroxy-2\'deoxyguanine (8-OHdG)                                        Kikuchi et al., [@B147]           48/22                     Increased (*p* \< 0.0001)
                                                                                                                              Isobe et al., [@B127]             20/20                     Increased (*p* \< 0.0001)
                                                  8-hydrosyguanosine (8-OHG)                                                  Kikuchi et al., [@B147]           48/22                     Increased
                                                                                                                              Abe et al., [@B2]                 24/15                     Increased 3-fold (*p* \< 0.001)
                                                  8-OHdG/8-OHG ratio                                                          Kikuchi et al., [@B147]           48/22                     Increased 2-fold (*p* \< 0.0005)
  Transition metals and related proteins          Iron                                                                        Campanella et al., [@B39]         13/5                      Normal
                                                                                                                              Pall et al., [@B243]              24/34                     Normal
                                                                                                                              Gazzaniga et al., [@B98]          11/22                     Normal
                                                                                                                              Takahashi et al., [@B289]         20/25                     Normal
                                                                                                                              Pan et al., [@B244]               NS/NS                     Normal
                                                                                                                              Jiménez-Jiménez et al., [@B134]   37/37                     Normal
                                                                                                                              Hozumi et al., [@B118]            20/15                     Normal
                                                                                                                              Forte et al., [@B89]              26/13                     Decreased (*p* \< 0.05)
                                                                                                                              Alimonti et al., [@B6]            42/20                     Decreased (*p* \< 0.05)
                                                                                                                              Qureshi et al., [@B265]           36/21                     Increased
                                                  Ferritin                                                                    Campanella et al., [@B39]         13/5                      Normal
                                                                                                                              Dexter et al., [@B66]             26/11                     Normal
                                                                                                                              Pall et al., [@B242]              24/21                     Normal
                                                                                                                              Kuiper et al., [@B157]            72 PDND/15 PDD/20 HC      Normal
                                                  Transferrin                                                                 Loeffler et al., [@B170]          12/11                     Normal
                                                  Copper                                                                      Campanella et al., [@B39]         13/5                      Normal
                                                                                                                              Gazzaniga et al., [@B98]          11/22                     Normal
                                                                                                                              Takahashi et al., [@B289]         20/25                     Normal
                                                                                                                              Pan et al., [@B244]               NS/NS                     Increased (*p* \< 0.05)
                                                                                                                              Jiménez-Jiménez et al., [@B134]   37/37                     Normal
                                                                                                                              Forte et al., [@B89]              26/13                     Normal
                                                                                                                              Alimonti et al., [@B6]            42/20                     Normal
                                                                                                                              Qureshi et al., [@B265]           36/21                     Normal
                                                                                                                              Boll et al., [@B30]               22/41                     Increased 2-fold
                                                                                                                              Pall et al., [@B243]              24/34                     Increased (*p* \< 0.001)
                                                                                                                              Hozumi et al., [@B118]            20/15                     Increased 2-fold (*p* \< 0.01)
                                                                                                                              Boll et al., [@B31]               49/26 (35 PD untreated)   Increased 1,5 fold
                                                  Ceruloplasmin                                                               Campanella et al., [@B39]         13/5                      Normal
                                                                                                                              Loeffler et al., [@B170]          12/11                     Normal
                                                  Ferroxidase                                                                 Boll et al., [@B30]               22/41                     Decreased activity by 20%
                                                                                                                              Boll et al., [@B31]               49/26 (35 PD untreated)   Decreased activity by 1.5-fold
                                                  Manganese                                                                   Gazzaniga et al., [@B98]          11/22                     Normal
                                                                                                                              Pan et al., [@B244]               NS/NS                     Normal
                                                                                                                              Jiménez-Jiménez et al., [@B134]   37/37 26/13               Normal Normal
                                                                                                                              Forte et al., [@B89]                                        
                                                                                                                              Alimonti et al., [@B6]            42/20                     Normal
                                                                                                                              Hozumi et al., [@B118]            20/15                     Increased 1.5-fold (*p* \< 0.05)
                                                  Zinc                                                                        Takahashi et al., [@B289]         20/25                     Normal
                                                                                                                              Pan et al., [@B244]               NS/NS                     Normal
                                                                                                                              Forte et al., [@B89]              26/13                     Normal
                                                                                                                              Jiménez-Jiménez et al., [@B134]   37/37                     Decreased (*p* \< 0.05)
                                                                                                                              Qureshi et al., [@B265]           36/21                     Decreased
                                                                                                                              Hozumi et al., [@B118]            20/15                     Increased 3-fold (*p* \< 0.01)
  Other metals                                    Selenium                                                                    Takahashi et al., [@B289]         20/25                     Normal
                                                                                                                              Qureshi et al., [@B265]           36/21                     Increased
                                                                                                                              Aguilar et al., [@B5]             28/43                     Increased only in untreated PD patients (*p* \< 0.01)
                                                  Chromium                                                                    Aguilar et al., [@B5]             28/43                     Normal
                                                                                                                              Alimonti et al., [@B6]            42/20                     Decreased by 50%
                                                  Magnesium                                                                   Hozumi et al., [@B118]            20/15                     Normal
                                                                                                                              Forte et al., [@B89]              26/13                     Normal
                                                                                                                              Alimonti et al., [@B6]            42/20                     Normal
                                                  Calcium                                                                     Pan et al., [@B244]               NS/NS                     Normal
                                                                                                                              Forte et al., [@B89]              26/13                     Normal
                                                                                                                              Alimonti et al., [@B6]            42/20                     Normal
                                                  Aluminum                                                                    Forte et al., [@B89]              26/13                     Decreased (*p* \< 0.05)
                                                                                                                              Alimonti et al., [@B6]            42/20                     Normal
                                                  Silicon                                                                     Forte et al., [@B89]              26/13                     Normal
                                                                                                                              Alimonti et al., [@B6]            42/20                     Decreased (*p* \< 0.05)
                                                  Cobalt                                                                      Alimonti et al., [@B6]            42/20                     Decreased (*p* \< 0.05)
                                                  Tin                                                                         Alimonti et al., [@B6]            42/20                     Decreased (*p* \< 0.05)
                                                  Lead                                                                        Alimonti et al., [@B6]            42/20                     Decreased by 50%
                                                  Various                                                                     Alimonti et al., [@B6]            42/20                     Normal levels of barium, bismuth, cadmium, mercury, molibdenum, nickel, antimony, strontium, thallium, vanadium, wolfram, and zirconium
  Nitric oxide metabolites/nitroxidative stress   Nitrates                                                                    Ikeda et al., [@B121]             11/17                     Normal
                                                                                                                              Molina et al., [@B211]            31/38                     Normal
                                                                                                                              Kuiper et al., [@B159]            103/20                    Decreased
                                                                                                                              Boll et al., [@B30]               22/41                     Increased 2-fold
                                                  Nitrites                                                                    Ikeda et al., [@B121]             11/17                     Normal
                                                                                                                              Ilic et al., [@B122]              33/?                      Normal
                                                                                                                              Kuiper et al., [@B159]            103/20                    Normal
                                                                                                                              Boll et al., [@B30]               22/41                     Increased 2-fold
                                                                                                                              Qureshi et al., [@B264]           16/14                     Increased 2-fold both in untreated (*n* = 6) and in levodopa-treated (*n* = 10) PD patients. Controls were young
                                                  Nitrotyrosine-containing proteins                                           Fernández et al., [@B82]          54/40                     Increased (*p* \< 0.01)
                                                                                                                              Aoyama et al., [@B13]             10/6                      Increased 1.8-fold
  Antioxidant enzymes or substances               Total superoxide-dismutase (SOD)                                            Marttila et al., [@B186]          26/26 OND                 Normal
                                                                                                                              De Deyn et al., [@B63]            12/58                     Normal
                                                  Cu/Zn-SOD (SOD-1)                                                           Ilić et al., [@B123]              31/16                     Increased (*p* \< 0.05)
                                                                                                                              Ilic et al., [@B122]              33/16                     Increased (*p* \< 0.05)
                                                                                                                              Boll et al., [@B30]               22/41                     Decreased (*p* = 0.021)
                                                  Mn-SOD (SOD-2)                                                              Aoyama et al., [@B13]             10/6                      Normal
                                                  Catalase                                                                    Marttila et al., [@B186]          26/26 OND                 Normal
                                                  Glutathione peroxidase (GPx)                                                Marttila et al., [@B186]          26/26 OND                 Normal
                                                  Glutathione reductase (GR)                                                  Ilić et al., [@B123]              31/?                      Increased
                                                                                                                              Ilic et al., [@B122]              33/?                      Increased
                                                  Reduced glutathione (GSH)                                                   Marttila et al., [@B186]          26/26 OND                 Normal
                                                                                                                              Tohgi et al., [@B295]             22/15                     Increased (*p* \< 0.02) in L-dopa treated patients (*n* = 8)
                                                                                                                              Konings et al., [@B150]           71 PD/13 PDND/21 HC       Normal
                                                  Oxidized glutathione (GSSG)                                                 LeWitt et al., [@B165]            48/57                     Decreased (*p* \< 0.01)
                                                                                                                              Tohgi et al., [@B295]             22/15                     Decreased (*p* \< 0.001) in untreated patients (*n* = 14)
                                                  Alpha-tocopherol (vitamin E)                                                Buhmann et al., [@B37]            70/60 OND/31 HC           Decreased by 44--48%
                                                                                                                              Tohgi et al., [@B295]             22/15                     Normal
                                                                                                                              Molina et al., [@B209]            34/47                     Normal
                                                  Alpha-tocopherol-quinone                                                    Tohgi et al., [@B295]             22/15                     Decreased (*p* \< 0.001) in untreated patients (*n* = 15)
                                                  Urate                                                                       Tohgi et al., [@B298]             11/14                     Normal
                                                                                                                              Constantinescu et al., [@B51]     6/18                      Normal
                                                                                                                              Ascherio et al., [@B18]           713/0                     Relation of higher CSF levels of urate with slower rates of clinical decline
                                                  Xantine (uric acid precursor)                                               LeWitt et al., [@B166]            217/26                    Normal
                                                  Ascorbate                                                                   Buhmann et al., [@B37]            70/60 OND/31 HC           Normal
                                                  Carnitine                                                                   Jiménez-Jiménez et al., [@B138]   29/29                     Normal
                                                  Oxidized coenzyme Q10/total Q10 ratio                                       Isobe et al., [@B127]             20/20                     Increased 18% (*p* \< 0.05)
                                                                                                                              Isobe et al., [@B129]             20/20                     Increased 18% (*p* \< 0.05)
                                                  Osteopontine                                                                Maetzler et al., [@B175]          30/30                     Increased 2-fold (*p* \< 0.002)

OND, other neurological controls; HC, healthy controls; PDND, Parkinson\'s disease non-demented.

Transition metals such as iron, copper, and manganese, act as prooxidant agents, although copper is also essential for the antioxidant function of the protein ceruloplasmin, and copper and manganese are constituents of the cytosolic Cu^+2^/Zn^+2^ and the mitochondrial Mn^+2^-superoxide-dismutases (SOD, protective against oxidative processes). Zinc has antioxidant activity and is a constituent of Cu^+2^/Zn^+2^-SOD (Jiménez-Jiménez et al., [@B134]). The results of studies with CSF levels of iron and copper are controversial (Table [3](#T3){ref-type="table"}), but a recent meta-analysis showed similar values in PD patients to controls (Mariani et al., [@B184]), thus suggesting that these metals are not useful as markers of PD.

Together with its role in glutamate excitotoxity, NO could contribute to oxidative stress mechanisms in the pathogenesis of PD by interacting with ferritin to release iron, inducing mitochondrial complex I damage (Molina et al., [@B212]), and by inducing nitrosylation of proteins (Fernández et al., [@B82]). However, studies on CSF levels of nitrates and nitrites have given controversial results (Table [3](#T3){ref-type="table"}).

Among other antioxidant enzymes and substances (Table [3](#T3){ref-type="table"}), one study involving an important number of early PD patients showed the relationship between the presence of relatively higher levels of urate and the slower rates of clinical decline (Ascherio et al., [@B18]), despite the fact that CSF urate levels were found to be similar in PD patients and controls in the same study.

Inflammatory and immunological markers
======================================

CSF interleukin (IL) 1-β levels were found to be normal in one study (Pirttila et al., [@B255]) and increased in three (Blum-Degen et al., [@B29]; Mogi et al., [@B206]; Mogi and Nagatsu, [@B202]), CSF IL-2 normal (Blum-Degen et al., [@B29]) or increased (Mogi et al., [@B206]; Mogi and Nagatsu, [@B202]), IL-4 increased (Mogi and Nagatsu, [@B202]), and CSF IL-10, IL-12, and interferon-gamma levels have been reported to be similar in PD patients and controls (Rota et al., [@B271]). CSF IL-6 levels have been found to be decreased in PD patients with major depression in comparison with patients with major depression without PD in one study (Pålhagen et al., [@B241]), while another 4 found higher CSF IL-6 in PD patients than in healthy controls (Blum-Degen et al., [@B29]; Mogi et al., [@B206]; Müller et al., [@B224]; Mogi and Nagatsu, [@B202]), and in one of them CSF IL-6 was correlated with PD severity (Müller et al., [@B224]). CSF tumor necrosis α (TNF-α) levels have been found to be increased (Mogi et al., [@B207]; Mogi and Nagatsu, [@B202]), leukotriene 4 (Irkeç et al., [@B124]), and α-1-antichymotrypsin normal (Pirttila et al., [@B255]), and β-2-microglobuline decreased in PD (Mogi et al., [@B203]; Mogi and Nagatsu, [@B202]). The CSF levels of the cytokine fractalkine have been found to be normal in PD patients and increased in multiple system atrophy (MSA), and Flt3 ligand normal in these two diseases (Shi et al., [@B276]). The presence of certain syalilated isoforms of Serpin A1 in the CSF has been related with the development of dementia in PD patients (Jesse et al., [@B133]).

CSF levels of pros-methylimidazol acetic acid, an isomer of the histamine metabolite tele-methylimidazol acetic acid, have been found to be decreased in PD (Prell et al., [@B260]), and were highly positively correlated with the severity of the disease (Prell and Green, [@B259]).

CSF complement 3 (C~3~) and factor H (FH) levels were reported to be normal in one study (Wang et al., [@B322]), while another described a decrease in several isoforms of C~3b,~C~4b~, FH, and factor B (Finehout et al., [@B85]), and another normal C~4d~ (Yamada et al., [@B339]). CSF levels of heat shock proteins Hsp65 and Hsp70 have been found to be increased (Fiszer et al., [@B86]), and PD patients have shown higher HLA-DR expression in CSF monocytes in comparison with controls (Fiszer et al., [@B87]).

Oligoclonal IgG bands have not been detected in the CSF of PD patients (Chu et al., [@B46]), but antibodies against DA neurons have been detected in 78% of PD patients and in only 3% of controls (Carvey et al., [@B40]), and the CSF of PD patients has shown a higher proportion of gamma-delta-T+ cells than in controls (Fiszer et al., [@B88]).

The results of studies on inflammatory and immunological markers in PD have a low number of patients and controls enrolled, and are inconclusive.

Growth and neurotrophic factors
===============================

CSF Brain Derived Neurotrophic Factor (BDNF) levels have been found to be similar in PD patients with major depression to those in patients with major depression without PD in one study (Pålhagen et al., [@B241]), while another described this value as increased in PD patients compared with controls (Salehi and Mashayekhi, [@B273]). CSF Transforming Growth Factor α (TGF-α) has been found to be increased in juvenile parkinsonism (Mogi and Nagatsu, [@B202]). TGF-β1 has been found to be increased (Mogi et al., [@B205], [@B206]; Vawter et al., [@B314]; Mogi and Nagatsu, [@B202]) or normal (Rota et al., [@B271]), and TGF-β2 increased (Vawter et al., [@B314]). CSF insulin-like growth factor-1 (IGF-1) and IGF binding proteins (IGFBPs) expression is increased in PD patients (Mashayekhi et al., [@B190]). Finally, a single study found a non-significant trend toward increased CSF levels of neuroregulins (which belong to the Epidermal Growth Factor or EGF family) in PD patients (Pankonin et al., [@B245]). The results of studies on growth and neurotrophic factors in PD, involving a low number of patients and controls, do not permit definitive conclusions.

Proteins involved in the pathogenesis of parkinson\'s disease
=============================================================

Microtubular associated protein *Tau* (MAPT)
--------------------------------------------

Because *MAPT* gene is one of the main genes involved in the risk for PD (Alonso-Navarro et al., [@B7]), the measurement of CSF protein *tau* levels are hypothetically useful as a marker of this disease. *Tau* protein is important for maintaining the stability of axonal microtubules involved in the mediation of fast axonal transport of synaptic constituents. Hyperphosphorylation of *tau* causes reduces binding affinity for microtubules, leading to their malfunction. Following neuronal damage, tau is released into extracellular space and may be increased in the CSF. *Tau* is an important component of the neurofibrillary tangles (pairwise, helical protein filaments which are found in the cytoskeleton or neuronal cells in Alzheimer\'s disease (AD) brains. CSF *tau* protein levels are increased in AD patients, and so are a useful marker for this disease. The high risk of PD patients of developing cognitive impairment or dementia patients makes measurement of CSF *tau* reasonable as a possible marker of this disease.

Many studies have shown similar CSF total *tau* and phosphorylated *tau* (phospho*tau*) in PD patients to controls (Blennow et al., [@B28]; Molina et al., [@B208]; Jansen Steur et al., [@B131]; Sjögren et al., [@B281]; Mollenhauer et al., [@B215]; Parnetti et al., [@B252], [@B249], [@B250],[@B251]; Ohrfelt et al., [@B236]; Compta et al., [@B48]; Alves et al., [@B9]; Montine et al., [@B219]; Aerts et al., [@B4]; van Dijk et al., [@B310]; Herbert et al., [@B114]). Several of these studies have shown increased CSF *tau* in demented PD patients (Mollenhauer et al., [@B215]; Compta et al., [@B48]). The 33 KDa/55 KDa *tau* isoforms ratio have also been found to be normal in PD (Borroni et al., [@B35], [@B34]), but decreased in progressive supranuclear palsy (PSP), and normal in patients with diffuse Lewy body disease (DLBD), demented PD patients (PDD), AD, and frontotemporal dementia (FTD) (Borroni et al., [@B35], [@B34]).

Some authors have found decreased CSF total *tau* and phospho*tau* levels when compared with controls (Mollenhauer et al., [@B213]; Shi et al., [@B276]; Kang et al., [@B146]) and similar levels in PD to PSP, DLBD, and MSA (Mollenhauer et al., [@B213]), while others found higher CSF *tau* in DLBD compared with PDD patients (Andersson et al., [@B11]), and still others higher CSF total *tau* in MSA than in PD patients (Herbert et al., [@B114]). Hall et al. ([@B112]) reported decreased CSF total *tau* and normal phospho*tau* both in PD and PDD, while total *tau* was increased in CBD and normal in PSP, DLBD, and MSA, and phospho*tau* was decreased in PSP and MSA in comparison with controls.

Přikrylová Vranová et al. ([@B262]) found increased CSF *tau* levels in PD patients with less than 2 years of evolution, and increased CSF *tau* levels which were higher in patients with PDD than in PD, and in PD than in controls, and similar CSF *tau* in DLDB than in controls (Vranová et al., [@B320]). This group and others found increased CSF total *tau* levels in patients with non-tremor variants of PD as compared to tremor-dominant PD and controls (Jellinger, [@B132]; Přikrylová Vranová et al., [@B261]). Compta et al. ([@B47]) described increased CSF *tau* levels in PD patients carrying the allele rs242557A. Siderowf et al. ([@B279]) showed a lack of association between baseline CSF *tau* levels and cognitive decline in PD patients. Patients with corticobasal degeneration (CBD) and PSP have shown higher CSF total and phospo*tau* levels (Aerts et al., [@B4]), and patients with DLBD showed similar CSF *tau* levels to PD patients in one study (Ohrfelt et al., [@B236]), while other authors found higher CSF *tau* levels in AD than in DLBD, in DLDB higher than in PDD, and in PDD higher than in PD (Parnetti et al., [@B252]).

Baseline CSF levels of total and phospho*tau* in the DATATOP study, involving 403 early PD patients, were negatively correlated with disease progression assessed with the Unified PD Rating Scale (UPDRS) (Zhang et al., [@B344]).

Beyer et al. ([@B26]) reported a lack of correlation between CSF levels of total and phospho*tau*, and ventricular size in 73 non-demented PD patients and 18 PD patients with mild cognitive impairment.

The results of the studies reported on CSF *tau* levels in PD are summarized in Table [4](#T4){ref-type="table"}. Although these results are not conclusive, CSF *tau* levels could be related to the progression of the disease (Zhang et al., [@B344]), and to the preservation of cognitive function in PD patients (Stewart et al., [@B283]).

###### 

**Results of studies on CSF tau and phosphotau levels in PD, other parkinsonian syndromes and controls**.

  **References**                       **Cases/Controls**                                                                                                                                                              **Main findings**
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Blennow et al., [@B28]               44 AD, 31 controls, 17 VAD, 11 FTD, 15 PDND, major depression                                                                                                                   CSF total tau and phosphorylated tau (phosphotau) higher in AD than in controls, VAD, FTD, PDND, and major depression (PDND similar than controls)
  Molina et al., [@B208]               26 PDND, 25 controls                                                                                                                                                            CSF total tau similar in PD and controls
  Jansen Steur et al., [@B131]         115 PD (48 with MMSE lower than 25) 15 controls                                                                                                                                 CSF total and phosphotau similar in PD (not related with MMSE scores) and controls
  Sjögren et al., [@B281]              19 AD, 14 FTD, 11 ALS, 15 PD, 17 controls                                                                                                                                       CSF total tau and phosphotau increased in AD compared with FTD (*p* \< 0.001), ALS (*p* \< 0.001), PD (*p* \< 0.001), and controls (p \< 0.001)
  Mollenhauer et al., [@B215]          73 PDD, 23 PDND, 41 controls (non-demented neurological patients)                                                                                                               CSF total tau significantly higher in PDD than in PDND and controls. This observation was most marked (*p* \< 0.05) in a subgroup of patients with PDD carrying the apolipoprotein genotype epsilon3/epsilon3
  Parnetti et al., [@B252]             19 DLBD, 18 PDD, 23 AD, 20 PDND, 20 controls                                                                                                                                    CSF total tau of DLBD patients significantly lower than in AD patients, but twofold to threefold higher than in PDD, PDND, or control subjects
                                                                                                                                                                                                                       CSF total tau levels similar in PDD and PDND
                                                                                                                                                                                                                       Phosphotau increased in the AD group only
  Borroni et al., [@B35]               21 PSP, 20 CBD, 44 FTD, 29 AD, 10 PDND, 15 DLBD, 27 controls                                                                                                                    CSF tau 33/55 kDa ratio significantly reduced in PSP when compared to controls and to patients with other neurodegenerative conditions
                                                                                                                                                                                                                       CSF tau 33/55 kDa ratio decrease correlated significantly with brainstem atrophy
  Borroni et al., [@B34]               78 patients with neurodegenerative disorders and 26 controls                                                                                                                    CSF tau 33/55 kDa ratio significantly decreased in patients with PSP (0.46 ± 0.16) when compared to healthy controls (*p* = 0.002), AD (*P* \< 0.001), FTD, CBD, PD, and DLBD (values in PD similar to those of controls)
  Ohrfelt et al., [@B236]              66 AD, 15 PD, 15 DLBD, 55 controls                                                                                                                                              CSF total tau and phosphotau increased significantly in AD, similar levels in PD, DLBD, and controls
  Compta et al., [@B48]                20 PDND, 20 PDD, 30 controls patients                                                                                                                                           CSF total tau and phosphotau higher in PDD than in PDND and controls (*P* \< 0.05). High CSF total tau and phospho-tau were associated with impaired memory and naming
  Alves et al., [@B9]                  109 PDND, 36 controls, 20 mild AD                                                                                                                                               CSF total tau and phosphotau similar in PD and controls
                                                                                                                                                                                                                       CSF tau did not correlate with cognitive measures
  Montine et al., [@B219]              150 controls (115 \>50 years; 24 amnestic Mild Cognitive Impairment (aMCI), 49 AD, 49 PD, 11 PDD 62 PD-CIND (cognitive imparment non-demented)                                  CSF total tau and phospho181-tau significantly increased in AD and aMCI in comparison with the other groups
                                                                                                                                                                                                                       Total tau similar in PDD, PDD and PD-CIND and controls
                                                                                                                                                                                                                       Phospho181-tau slightly decreased when compared with controls \>50 years
  Přikrylová Vranová et al., [@B262]   32 PD, 30 controls                                                                                                                                                              CSF total tau and total tau/beta-amyloid (1-42) ratio higher in PD than in controls (*p* = 0.045 and 0.033, respectively)
  Siderowf et al., [@B279]             45 PD, longitudinal follow-up at least 1 year                                                                                                                                   No association between CSF total tau and phospo181-tau and cognitive decline
  Aerts et al., [@B4]                  21 PSP, 12 CBD, 28 PD, 49 controls                                                                                                                                              CSF total tau CBD \> PSP \> PD = controls
                                                                                                                                                                                                                       CSF phospotau CBD \> PSP = PD = controls
  Parnetti et al., [@B249]             38 PD, 32 DLBD, 48 AD, 31 FTD, 32 controls with other neurological diseases (*n* = 32)                                                                                          CSF total tau and phosphotau AD \> FTD \> DLBD = PD = controls
  Shi et al., [@B276]                  137 controls, 126 PD, 50 AD and 32 MSA                                                                                                                                          CSF total tau and phosphotau AD \> controls \> PD = MSA
  Mollenhauer et al., [@B213]          Cross-sectional cohort: 51 PD, 29 MSA, 55 DLBD, 62 AD, and 72 neurological controls                                                                                             CSF total tau AD \> DLBD \> PD = controls = MSA
  Mollenhauer et al., [@B213]          Validation cohort: 275 PD, 15 MSA, 55 66 DLBD, 8 PSP,22 normal pressure hydrocephalus (NPH) and 23 neurological controls                                                        CSF total tau MSA \< DLBD = PD \< DLBD \< controls
  Andersson et al., [@B11]             47 DLBD, 17 PDD (*n* = 17)                                                                                                                                                      CSF total-tau higher in DLBD than in PDD
                                                                                                                                                                                                                       CSF phosphotau similar in DLBD and PDD
  Compta et al., [@B47]                38 PD patients (19 PDD, 19 PDND). All cases were genotyped for a series of tau gene polymorphisms rs1880753, rs1880756, rs1800547, rs1467967, rs242557, rs2471738, and rs7521   The A-allele rs242557 polymorphism was the only tau gene variant significantly associated with higher CSF tau and phospho-tau levels, under both dominant and dose-response model. This association depended on the presence of dementia, and was only observed in individuals with low (\<500 pg/mL) CSF Aβ levels
  Hall et al., [@B112]                 90 PDND, 33 PDD, 70 DLBD, 48 AD, 45 PSP, 48 MSA, 12 CBD, 107 controls                                                                                                           CSF total tau AD \> MSA = CBD \> PSP = Controls = DLBD \> PDND = PDD
                                                                                                                                                                                                                       CSF phosphotau increased in AD, AD \> PDD = DLBD = controls = CBD \> PDND \> PSP = MSA
  Přikrylová Vranová et al., [@B261]   48 PD (17 early-onset PD, 15 tremor dominant, 16 non-tremor-dominant), 19 neurological controls, 18 AD                                                                          CSF tau and index tau/amiloid beta42 increased in non-tremor-dominant PD compared with controls, and other PD groups, and siminar to those of AD
  Jellinger, [@B132]                   12 PD (6 tremor-dominant PD and 6 non-tremor-dominant PD), 27 AD, 17 controls                                                                                                   CSF total tau higher in AD compared with the other groups, and higher in tremor-dominant PD compared with non-tremor dominant PD and controls
  van Dijk et al., [@B310]             52 PD, 50 controls                                                                                                                                                              CSF total tau and phosphotau similar in PD and controls
  Kang et al., [@B146]                 63 PD, 39 controls                                                                                                                                                              CSF total tau and phosphotau181 significantly lower in PD than in controls
  Zhang et al., [@B344]                403 early stage PD patients enrolled in the DATATOP study                                                                                                                       Baseline CSF phosphotau/total tau and phosphotau/amyloid beta significantly and negatively correlated with the rates of the Unified Parkinson Disease Rating Scale change
  Beyer et al., [@B26]                 73 PDND, 18 PD with mild cognitive impairment                                                                                                                                   No associations between CSF total tau and phosphotau and hippocampal atrophy
  Herbert et al., [@B114]              43 PD, 23 MSA, 30 controls                                                                                                                                                      CSF total tau significantly lower in PD than in MSA, but similar to those of controls
                                                                                                                                                                                                                       CSF phosphotau similar in PD, MSA and controls
  Parnetti et al., [@B250]             71 PD (8 of 44 carriers of a mutation in the beta-glucocerebrosidase gene (*GBA1*) 45 controls with other neurological disases                                                  CSF total tau and phosphotau similar in PD and controls
  Parnetti et al., [@B251]             44 PD and 25 controls with other neurological diseases                                                                                                                          CSF total tau and phosphotau similar in PD and controls, and unrelated with prognosis and cognitive impairment
  Vranová et al., [@B320]              27 PDND, 14 PDD, 14 DLBD, 17 AD 24 controls                                                                                                                                     CSF total tau AD \> PDD \> PDND \> DLBD = controls

AD, Alzheimer\'s disease; PD, Parkinson\'s disease; VAD, vascular dementia; FTD, frontotemporal dementia; PDND, PD non-demented; PD, PD demented; MMSE, MiniMental State Examination; DLBD, diffuse Lewy body disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA, multiple system atrophy; aMCI, Amnestic Mild Cognitive Impairment; PD-CIND, PD with cognitive imparment non-demented; NPH, normal pressure hydrocephalus.

Alpha-synuclein
---------------

Alpha-synuclein (α-synuclein) is a 140 amino acid-long presynaptic protein, which is the major component of the Lewy bodies (the neuropatologic hallmark of PD), and has been implicated in the pathogenesis of PD and in synucleinopathies such as MSA and DLBD. Mutations of the α-*synuclein* (*SNCA*) gene are related with early-onset monogenic familial PD and are associated with increased risk for sporadic PD (Alonso-Navarro et al., [@B7]). Although early studies failed to detect the native form of α-synuclein in the CSF of PD and control patients (Jakowec et al., [@B130]), later studies have detected monomeric SNC in the CSF, with similar levels in PD patients and controls (Borghi et al., [@B33]). Several studies have found similar CSF total α-synuclein levels in PD patients and in controls (Woulfe et al., [@B335]; Ohrfelt et al., [@B236]; Park et al., [@B248]; Parnetti et al., [@B249]; Tateno et al., [@B290]) and others decreased CSF α-synuclein in PD (Tokuda et al., [@B306]; Hong et al., [@B117]; Mollenhauer et al., [@B213], [@B214]; Hall et al., [@B112]; Wang et al., [@B323]; Kang et al., [@B146]; Wennström et al., [@B329]; Parnetti et al., [@B250],[@B251]; Mondello et al., [@B216]; van Dijk et al., [@B309]), DLBD (Parnetti et al., [@B249]; Wennström et al., [@B329]), MSA (Wang et al., [@B323]; Mondello et al., [@B216]), and PSP (Wang et al., [@B323]). Four studies have reported increased CSF oligomeric α-synuclein levels in PD compared with controls (Tokuda et al., [@B305]; Park et al., [@B248]; Parnetti et al., [@B250],[@B251]), and one of them showed increased CSF α-Syn in PD patients compared with patients with PSP and AD (Tokuda et al., [@B305]). Wang et al. ([@B323]) found increased CSF levels of the phosphorylated α-synuclein phospho-Ser129 (PS-129) in PD patients when compared with controls, but lower levels in MSA and PSP of this protein than in PD patients and controls.

Aerts et al. ([@B3]) found similar CSF α-synuclein levels in PD patients to DLBD, PSP, and MSA. Hall et al. ([@B112]) found higher CSF α-synuclein in PSP than in PD, PDD, DLBD, and MSA. Tateno et al. ([@B290]) reported similar CSF α-synuclein levels in PD, MSA, DLBD, and controls but higher CSF α-synuclein levels in AD patients, while Ohrfelt et al. ([@B236]) found higher CSF α-Syn levels in AD than in DLDB and PD, and in DLBD than in PD patients. Foulds et al. ([@B90]) found similar post-mortem CSF total α-synuclein levels in PD, MSA, DLBD, and PSP, but increased CSF levels of phosforylated oligomers in MSA.

van Dijk et al. ([@B309]) reported a lack of relation between CSF α-synuclein levels and striatal dopaminergic deficit measured by dopamine transporter binding and single photon emission computed tomography. In addition, a recent study by Shi et al. ([@B277]) described a lack of relation between the loss of striatal dopaminergic function, assessed by positron emission tomography (PET), and CSF α-synuclein levels, in asymptomatic carriers of mutations in the *LRRK2* gene. CSF neurosin (a protease that degrades α-synuclein) levels have been found to be decreased (Wennström et al., [@B329]).

Lower baseline CSF α-synuclein levels in the DATATOP study predicted a better preservation of cognitive function in early PD patients with up to 8 years of follow-up (Stewart et al., [@B283]).

The results of the studies reported on CSF α-synuclein levels in PD are summarized in Table [5](#T5){ref-type="table"}. The majority of recent studies have shown decreased CSF α-synuclein levels both in PD and in other synucleopathies. Therefore, this should be a useful marker to distinguish this disease from controls, but not to distinguish among synucleopathies.

###### 

**Results of studies on CSF alpha-synuclein and phosphotau levels in PD, other parkinsonian syndromes and controls**.

  **References**                **Cases/Controls**                                                                                                                **Main findings**
  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Borghi et al., [@B33]         12 PD, 10 controls                                                                                                                Identification of a 19 kDa band that corresponds to monomeric α-synuclein (similar levels in PD and controls)
  Woulfe et al., [@B335]        5 PD, 4 controls                                                                                                                  Similar anti-α-synuclein antibodies in PD and controls
  Tokuda et al., [@B306]        33 PD, 38 controls (9 healthy and 29 with OND)                                                                                    CSF α-synuclein levels significantly lower in PD than in controls (*p* \< 0.0001)
  Ohrfelt et al., [@B236]       66 AD, 15 PD, 15 DLBD, 55 controls                                                                                                CSF α-synuclein AD \> Controls = DLBD = PD
  Hong et al., [@B117]          117 PD, 132 controls, 50 AD                                                                                                       CSF α-synuclein PD \< Controls = AD (after correcting for hemoglobin levels)
  Tokuda et al., [@B305]        32 PD, 28 controls (12 healthy and 16 with OND)                                                                                   CSF α-synuclein oligomers and oligomers/total-α-synuclein ratio in CSF higher in PD group (*p* \< 0.0001)
  Tokuda et al., [@B305]        25 PD, 18 PSP, 35 AD, 43 controls                                                                                                 CSF α-synuclein PD \> PSP = Controls \> AD
  Parnetti et al., [@B249]      38 PD, 32 DLBD, 48 AD, 31 FTD, 32 controls with other neurological diseases (*n* = 32)                                            CSF α-synuclein Controls \> PD \> DLBD = AD = FTD
  Mollenhauer et al., [@B213]   Cross-sectional cohort: 51 PD, 29 MSA, 55 DLBD, 62 AD, and 72 neurological controls                                               CSF α-synuclein PD \< DLBD \< MSA \< controls \< AD
  Kang et al., [@B146]          Validation cohort: 275 PD, 15 MSA, 55 66 DLBD, 8 PSP, 22 NPH, and 23 neurological controls                                        CSF α-synuclein MSA \< DLBD = PD \< NPH = PSP \< controls
  Park et al., [@B248]          23 PD, 29 neurological controls                                                                                                   CSF α-synuclein oligomer significantly higher in PD than in neurological controls
  Kang et al., [@B146]          63 PD, 39 controls                                                                                                                Slightly, but significantly, lower CSF levels of α-synuclein in PD compared with healthy controls
                                                                                                                                                                  Lower levels of CSF α-synuclein associated with increased motor severity
  Hall et al., [@B112]          90 PDND, 33 PDD, 70 DLBD, 48 AD, 45 PSP, 48 MSA, 12 CBD, 107 controls                                                             CSFα-synuclein AD \> PSP = Controls \> PDD = DLBD = MSA = CBD = PDND
  Tateno et al., [@B290]        9 AD, 6 DLBD, 11 PD, 11 MSA, 11 neurological controls                                                                             CSFα-synuclein levels in AD higher than in controls (*P* \< 0.05), and significantly lower in PD (*P* \< 0.001), DLBD (*P* \< 0.01), and MSA (*P* \< 0.05) when compared with AD
  Wang et al., [@B323]          Discovery series: 93 PD, 26 AD, 78 controls, 33 PSP, 16 MSA                                                                       CSF Phosphorylated α-synuclein (PS-129) PD \> Controls \> AD \> MSA = PSP
                                Replication series: 116 PD, 50 AD, 126 controls, 27 PSP, 25 MSA                                                                   CSFα-synuclein MSA \< PD \< PSP \> AD = Controls
                                                                                                                                                                  CSF PS-199/α-synuclein ratio MSA \> PK \> AD \> PSP = Controls
  Aerts et al., [@B3]           58 PD, 47 MSA, 3 DLBD, 22 Vascular Parkinsonsim, 10 PSP, 2 CBD, 57 controls                                                       CSFα-synuclein did not differ significantly among the study groups
  Foulds et al., [@B90]         13 PDND, 10 PD with cognitive impairment, 16 PDD, 17 DLBD, 12 PSP, 8 MSA, 20 controls (ventricular CSF obtained post-mortem)      CSF total α-synuclein, oligomeric α-synuclein and phosphorylated α-synuclein similar in PDND, PDCI, PDD, DLBD, PSP, MSA, and control groups
                                                                                                                                                                  CSF oligomeric phosphorylated α-synuclein significantly higher in MSA (*p* \< 0.001) when compared with the other study groups
  Shi et al., [@B277]           8 symptomatic and 18 asymptomatic carriers of the G2019 mutation in the *LRRK2* gene                                              Lack of correlation between PET scan evidence of loss of striatal dopaminergic and CSF α-synuclein levels
  Mollenhauer et al., [@B214]   78 PD (drug naive), 48 controls                                                                                                   CSF α-synuclein lower in PD than in controls
  Wennström et al., [@B329]     52 controls, 46 AD,38 PDND, 22 PDD, 33 DLBD                                                                                       AD \> controls \> DLBD \> PD \> PDD
  Parnetti et al., [@B250]      71 PD (8 of 44 carriers of a mutation in the beta-glucocerebrosidase gene (*GBA1*) 45 controls with other neurological diseases   CSF α-synuclein lower and oligomeric/total α-synuclein ratio higher in PD than in controls
  Parnetti et al., [@B251]      44 PD and 25 controls with other neurological diseases                                                                            CSF total α-synuclein lower and oligomeric α-synuclein higher in PD than in controls. No relation with prognosis and cognitive impairment
  van Dijk et al., [@B309]      53 PD, 50 controls                                                                                                                CSF α-synuclein levels reduced in patients with PD, but not correlated with measures of disease severity, and striatal dopaminergic deficit assessed with neuroimaging
  Mondello et al., [@B216]      22 controls, 52 PD, 34 MSA, 32 PSP, 12 CBD                                                                                        CSF α-synuclein MSA \< PD \< PSP \< CBD \< Controls
  Stewart et al., [@B283]       304 early PD patients enrolled in the DATATOP study. Longitudinal follow-up                                                       CSF α-synuclein showed a longitudinal decrease over follow-up period
                                                                                                                                                                  CSF α-synuclein was not correlated with the rate of clinical progression of the motor symptoms
                                                                                                                                                                  Lower basal levels of CSF α-synuclein were associated with better preservation of cognitive function

AD, Alzheimer\'s disease; PD, Parkinson\'s disease; FTD, frontotemporal dementia; PDND, PD non-demented; PD, PD demented; OND, Other neurological diseases; DLBD, diffuse Lewy body disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA, multiple system atrophy; NPH, normal pressure hydrocephalus.

Amyloid-beta
------------

Amyloid beta (Aβ) are a group of different lengths peptides resulting from the enzymatic cleavage of the amyloid precursor protein (APP). The most common is the 42 amino-acid long Aβ42. These peptides have a differential trend toward aggregation (specially Aβ1-42) to form amyloid plaques, one of the pathological hallmarks of AD and DLBD. The increased risk for developing cognitive impairment and dementia of PD patients in comparison with the general population makes it reasonable to link AD markers such as Aβ42 to PDD. Several studies have shown similar (Holmberg et al., [@B115]; Mollenhauer et al., [@B215]; Ohrfelt et al., [@B236]; Přikrylová Vranová et al., [@B262]; Aerts et al., [@B4]; Parnetti et al., [@B249]; van Dijk et al., [@B310]) or decreased (Sjögren et al., [@B281]; Compta et al., [@B48]; Mollenhauer et al., [@B213]; Shi et al., [@B276]; Kang et al., [@B146]; Nutu et al., [@B234]; Vranová et al., [@B320]) CSF Aβ1-42 (Aβ1-42) in PD patients, with the exception of one study which reports increased levels (Parnetti et al., [@B251]). Other found decreased CSF Aβ-1-42 (Mollenhauer et al., [@B215]; Compta et al., [@B48]; Alves et al., [@B9]; Montine et al., [@B219]; Siderowf et al., [@B279]) and Aβ1-40 (Alves et al., [@B9]) and Aβ1-38 (Alves et al., [@B9]) only in PDD patients or in PD patients with memory impairment.

Baseline CSF Aβ levels in the DATATOP study, were negatively correlated with disease progression assessed with UPDRS (Zhang et al., [@B344]). Baseline CSF levels of Aβ1-42 in two studies (Siderowf et al., [@B279]; Parnetti et al., [@B251]); and the combination of lower baseline CSF Aβ, worse verbal learning, semantic fluency and visuoperceptual scores, and thinner superior-frontal/anterior cingulated in precentral regions by 3T-brain-Magnetic Resonance Imaging in another (Compta et al., [@B49]) have been associated with further cognitive decline in PD patients.

CSF Aβ1-42 levels have been reported as decreased (Parnetti et al., [@B252]; Andersson et al., [@B11]; Parnetti et al., [@B249]) or similar (Ohrfelt et al., [@B236]; Nutu et al., [@B234]) in DLBD than in PDD and PD patients, decreased in MSA (Holmberg et al., [@B115]; Shi et al., [@B276]), and decreased in DLBD in comparison with PD, PDD (Hall et al., [@B112]; Vranová et al., [@B320]), PSP, MSA, and CBD (Hall et al., [@B112]).

Alves et al. ([@B10]) reported that patients with PD with the postural instability-gait disorders (PIGD) phenotype had significantly reduced CSF Aβ42, Aβ38, Aβ42/40, and Aβ38/40 levels compared with patients with the tremor-dominant phenotype and controls.

Nutu et al. ([@B233]) described lower CSF levels of Aβ1-15/16 in PD, PDD, PSP, and MSA compared to CBD, AD, and controls.

Beyer et al. ([@B26]) reported a correlation between CSF levels of Aβ38, Aβ40, and Aβ42, and ventricular size in 73 non-demented PD patients and 18 PD patients with mild cognitive impairment.

The results of the studies reported on CSF Aβ levels in PD are summarized in Table [6](#T6){ref-type="table"}. Many of these studies suggest the potential usefulness of CSF Aβ1-42 levels to predict cognitive impairment in PD patients.

###### 

**Results of studies on CSF amiloyd beta (Aβ) levels in PD, other parkinsonian syndromes and controls**.

  **References**                       **Cases/Controls**                                                                                                                               **Main findings**
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sjögren et al., [@B281]              19 AD, 14 FTD, 11 ALS, 15 PD, 17 controls                                                                                                        CSF Aβ42 markedly decreased in AD = ALS \< FTD \< PD \< controls
  Holmberg et al., [@B115]             36 MSA, 48 PD, 15 PSP, 32 controls                                                                                                               CSF Aβ42 MSA \< PSP = controls = PD
  Mollenhauer et al., [@B215]          73 PDD, 23 PDND, 41 controls (non-demented neurological patients)                                                                                CSF Aβ42 lower in the PDD patients compared to PDND patients and controls. This observation was most marked (*p* \< 0.05) in a subgroup of patients with PDD carrying the apolipoprotein genotype epsilon3/epsilon3
  Parnetti et al., [@B252]             19 DLBD, 18 PDD, 23 AD, 20 PDND, 20 controls                                                                                                     DLBD showed the lowest mean CSF Aβ42 levels, with a negative association to dementia duration. PDD patients had mean CSF Aβ42 similar to those seen in PD patients
  Ohrfelt et al., [@B236]              66 AD patients, 15 PD patients, 15 patients with dementia with Lewy bodies (DLBD) and 55 cognitively normal controls                             CSF Aβ42 AD \< DLBD \< PD = Controls
  Compta et al., [@B48]                20 PDND, 20 PDD, 30 controls patients                                                                                                            CSF Aβ42 ranged from high (controls) to intermediate (PDND) and low (PDD) levels (*P* \< 0.001). In all PD and PDD patients, in PDND, CSF Aβ42 was related with phonetic fluency
  Alves et al., [@B9]                  109 PDND, 36 controls, 20 mild AD                                                                                                                CSF Aβ42 (19%; *p* = 0.009), Aβ40 (15.5%; *p* = 0.008), and Aβ38 (23%; *p* = 0.004) significantly decreased in PD compared with controls
                                                                                                                                                                                        CSF Aβ42 reductions in PD less marked than in AD (53%; *p* = 0.002)
                                                                                                                                                                                        Associations between CSF levels of Aβ42 (β = 0.205; *p* = 0.019), Aβ40 (β = 0.378; *p* \< 0.001), and Aβ38 (β = 0.288; *p* = 0.001) and memory impairment, but not executive-attentional or visuospatial dysfunction
  Montine et al., [@B219]              150 controls (115 \>50 years; 24 amnestic Mild Cognitive Impairment (aMCI), 49 AD, 49 PD, 11 PDD 62 PD-CIND (cognitive imparment non-demented)   CSF Aβ42 levels reduced in AD (*p* \< 0.001), PD-CIND (*P* \< 0.05), and PDD (*P* \< 0.01), and similar to those of controls in PD
  Přikrylová Vranová et al., [@B262]   32 PD, 30 controls                                                                                                                               CSF Aβ1-42 similar in PD and controls
  Siderowf et al., [@B279]             45 PD, longitudinal follow-up at least 1 year                                                                                                    Lower baseline CSF Aβ1-42 associated with more rapid cognitive decline
                                                                                                                                                                                        Subjects with CSF Aβ1-42 levels =192 pg/mL declined an average of 5.85 (95% confidence interval 2.11--9.58, *p* = 0.002) points per year more rapidly on the DRS-2 than subjects above that cutoff, after adjustment for age, disease duration, and baseline cognitive status
  Aerts et al., [@B4]                  21 PSP, 12 CBD, 28 PD, 49 controls                                                                                                               CSF Aβ1-42 similar in CBD, PSP, PD, and controls
  Parnetti et al., [@B249]             38 PD, 32 DLBD, 48 AD, 31 FTD, 32 controls with other neurological diseases                                                                      CSF Aβ1-42 controls = PD \> DLBD = AD = FTD
  Shi et al., [@B276]                  137 controls, 126 PD, 50 AD and 32 MSA                                                                                                           CSF Aβ1-42 controls = PD = \_MSA \> AD
  Mollenhauer et al., [@B213]          Validation cohort: 275 PD, 15 MSA, 55 66 DLBD, 8 PSP, 22 NPH, and 23 neurological controls                                                       CSF Aβ1-42 DLBD \< MSA = NPH = PD \< controls \< PSP
  Andersson et al., [@B11]             47 DLBD, 17 PDD                                                                                                                                  Aβ42 lower in DLBD than in PDD
  Kang et al., [@B146]                 63 PD, 39 controls                                                                                                                               Slightly, but significantly, lower levels of Aβ1-42 in PD compared with controls
  Hall et al., [@B112]                 90 PDND, 33 PDD, 70 DLBD, 48 AD, 45 PSP, 48 MSA, 12 CBD, 107 controls                                                                            CSF Aβ1-42 AD \< DLBD = PDD = PSP = MSA = CBD = PDND = Controls
  Přikrylová Vranová et al., [@B261]   48 PD (17 early-onset PD, 15 tremor-dominant, 16 non-tremor-dominant), 19 neurological controls, 18 AD                                           CSF Aβ42 lower in AD than in the other groups, and lower in non-tremor-dominant PD compared with controls
  Jellinger, [@B132]                   12 PD (6 tremor-dominant PD and 6 non-tremor-dominant PD), 27 AD, 17 controls                                                                    CSF Aβ42 lower in tremor-dominant PD than in non-tremor-dominant PD and AD, and lower in these three groups than in controls
  van Dijk et al., [@B310]             52 PD, 50 controls                                                                                                                               CSF Aβ42 similar in PD and controls
  Zhang et al., [@B344]                403 early stage PD patients enrolled in the DATATOP study                                                                                        CSF baseline levels of Aβ42 weakly but negatively correlated with baseline Unified Parkinson Disease Rating Scale total scores
  Beyer et al., [@B26]                 73 PDND, 18 PD with mild cognitive impairment                                                                                                    Association between CSF Aβ38, Aβ40, and Aβ42 with the radial distance of the occipital and frontal horns of the lateral ventricles in PDND. Negative association between CSF Aβ38 and Aβ42 with enlargement in occipital and frontal horns of the lateral ventricles in the pooled sample, and with enlargemente of the occipital horns in PD with mild cognitive impairment
  Nutu et al., [@B234]                 43 PDND, 33 PDD, 51 DLBD, 48 AD, 107 controls                                                                                                    CSF Aβ1-40 AD \< DLDB \< PDD \< PDND = controls
                                                                                                                                                                                        CSF Aβ1-42 PDD = DLBD = PDND \< controls = AD
                                                                                                                                                                                        CSF Aβ1-40/Aβ1-42 ratio AD \< DLDB \< PDD = controls = PD
  Compta et al., [@B49]                27 PDND, longitudinal following (11 developed dementia)                                                                                          Lower CSF amyloid-β predicted development of dementia together with worse verbal learning, semantic fluency and visuoperceptual scores, and thinner superior-frontal/anterior cingulate and precentral regions
  Alves et al., [@B10]                 99 PD *de novo* (39 with postural instability/gait disorders --PIGD---and 60 tremor-dominant---TD), 46 controls                                  CSF Aβ42, Aβ38, Aβ42/40, and Aβ38/40 levels significantly reduced in PIGD phenotype compared with TD phenotype and with controls (TD similar to controls)
  Nutu et al., [@B233]                 90 PDND, 32 PDD, 68 DLBD, 48 AD, 45 PSP, 46 MSA, 12 CBD, 107 controls                                                                            Significantly lower levels of Aβ1-15/16 were detected in PD, PDD, PSP, and MSA compared to other neurodegenerative diseases and controls
  Parnetti et al., [@B251]             44 PD and 25 controls with other neurological diseases                                                                                           CSF Aβ42 lower in PD than in controls. This value was related with cognitive impairment
  Vranová et al., [@B320]              27 PDND, 14 PDD, 14 DLBD, 17 AD 24 controls                                                                                                      CSF Aβ42 PDND \> PDD \> DLBD \>AD \> controls

AD, Alzheimer\'s disease; PD, Parkinson\'s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; PDND, PD non-demented; PD, PD demented; DLBD, diffuse Lewy body disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA, multiple system atrophy; aMCI, Amnestic Mild Cognitive Impairment; PD-CIND, PD with cognitive imparment non-demented; NPH, normal pressure hydrocephalus; PIGD, Postural instability and gait disorder; TD, tremor-dominant.

Neurofilament proteins
----------------------

Abnormal accumulation in the cytoplasm of neurofilaments (NF), members of the cytoskeleton proteins expressed by neurons, have been detected in neurodegenerative diseases including AD, MSA, DLBD, and PD. CSF levels of neurofilament light (NFL) proteins have been found normal in PD patients (Constantinescu et al., [@B52]; Hall et al., [@B112]), and increased in patients with PSP (Holmberg et al., [@B116]; Constantinescu et al., [@B52]; Hall et al., [@B112]), MSA (Holmberg et al., [@B116]; Constantinescu et al., [@B52]; Hall et al., [@B112]), CBD (Constantinescu et al., [@B52]; Hall et al., [@B112]), and PDD (Hall et al., [@B112]).

CSF neuronal thread protein (NTP) levels have been found increased when compared with controls and decreased when compared with AD patients in one study (de la Monte et al., [@B65]), and similar to those of controls in another (Yamada et al., [@B338]). CSF annexine V has been found to be decreased in PD (Vermes et al., [@B316]). Glial fibrilar acidic protein (GFAP) has been found to be normal in the CSF of PD, MSA, PSP, and CBD patients (Constantinescu et al., [@B52]). CSF levels of the glial activation marker YKL-40 have been found to be decreased in PD, MS, PSP, and CBD (Olsson et al., [@B237]).

Other proteins
--------------

Defects in the gene encoding DJ-1 protein cause an autosomal recessive early-onset PD, PARK7 (Alonso-Navarro et al., [@B7]). This protein is also a marker of oxidative stress. CSF levels of DJ-1 protein have been found to be increased in PD in 2 studies (Waragai et al., [@B324]; Herbert et al., [@B114]) and decreased in another 2 (Shi et al., [@B276]; Hong et al., [@B117]). One of these studies described decreased CSF DJ-1 in MSA as well (Shi et al., [@B276]), and other increased DJ-1 in MSA compared with PD and with controls (Herbert et al., [@B114]). Shi et al. ([@B277]) described a lack of relation between the loss of striatal dopaminergic function and CSF DJ-1 levels in asymptomatic carriers of mutations in the *LRRK2* gene (PARK8). The results on DJ-1 are, therefore, inconsistent and should not be considered as a marker of PD.

Defects in the gene encoding ubiquitin carboxy-terminal hydrolase 1 (UCH-L1) cause familial PD, PARK5. A recent study found decreased CSF UCH-L1 levels in PD, MSA, and PSP compared with controls (Mondello et al., [@B216]).

Among proteins related with apoptosis, Bcl-2 protein has not been detected in the CSF of PD patients (Mogi et al., [@B204]; Mogi and Nagatsu, [@B202]). CSF levels of clusterin have been reported to be increased (Přikrylová Vranová et al., [@B262]; Vranová et al., [@B320]) or normal (van Dijk et al., [@B310]), tissue transglutaminase (Vermes et al., [@B315]) increased in PD, and cystatin C normal in PD (Přikrylová Vranová et al., [@B262]; Yamamoto-Watanabe et al., [@B341]) and decreased in MSA (Yamamoto-Watanabe et al., [@B341]).

Studies measuring CSF levels of lysosomal hydrolases (involved in the α-Syn degradation) found decreased (Balducci et al., [@B19]), normal (van Dijk et al., [@B311]), or increased (Parnetti et al., [@B250]) β-hexosaminidase, increased cathepsin E (van Dijk et al., [@B311]), decreased α-mannosidase (Balducci et al., [@B19]), decreased (Balducci et al., [@B19]) or normal β-mannosidase (Mollenhauer et al., [@B213]; van Dijk et al., [@B311]), decreased α-fucosidase (van Dijk et al., [@B311]), β-glucocerebrosidase decreased (Balducci et al., [@B19]; Parnetti et al., [@B250]) or normal (van Dijk et al., [@B311]), β-galactosidase increased (van Dijk et al., [@B311]) or normal (Balducci et al., [@B19]; Parnetti et al., [@B250]), and cathepsin D normal (van Dijk et al., [@B311]) in PD patients compared with controls.

CSF Prion protein (PrP) (Meyne et al., [@B201]) and tetranectin (involved in tissue remodeling) (Hong et al., [@B117]) levels have been found to be decreased, and apolipoprotein A-1 normal (Wang et al., [@B321]) in PD patients. CSF levels of transthyretin (TTR, a clearance protein produced in the choroid plexus) have been found to be increased in Lewy body diseases, including PD, PDD, and DLBD in relation with controls (Maetzler et al., [@B176]). CSF levels of the soluble proteoglycan NG2 (sNG2), involved in proliferation, migration, and differentiation of perycites and NG2 cells in the brain, have been found to be similar in PD patients and controls, and decreased in DLBD (Nielsen et al., [@B231]).

In PD patients there are reports of decreased CSF post-proline cleaving enzyme (Hagihara and Nagatsu, [@B110]), increased dipeptidyl-aminopeptidase II (Hagihara et al., [@B111]), normal dipeptidyl-aminopeptidase IV (Hagihara et al., [@B111]), and normal glutamic oxaloacetic transaminase (GOT) (Steen and Thomas, [@B282]; Weiss et al., [@B327]; Qureshi et al., [@B264]) and glutamic pyruvic transaminase (GPT) (Weiss et al., [@B327]) levels.

Other compounds
===============

In patients with PD there have been reports of normal CSF levels of the proteoglycan N-acetyl neuraminic acid (Lipman and Papadopoulos, [@B167]), and CSF insulin levels (Jiménez-Jiménez et al., [@B136]) have been found normal in PD patients.

The CSF levels of corticosterone (Pålhagen et al., [@B241]) and neuroactive steroids such as allopregnanolone (THP) and 5 α-dihydroprogesterone (DHP) (di Michele et al., [@B67]) have been found to be decreased in PD. Björkhem et al. ([@B27]) reported that 10% of the PD patients were found to have increased CSF levels of 24S-hydroxycholesterol, and that there was a significant correlation between this value and duration of the disease. Lee et al. ([@B164]) described a significant increase in the CSF levels of the polyunsaturated fatty acid eicosapentanoic acid (EPA) in patients with PD and MSA.

Paik et al. ([@B240]) measured several polyamines in the CSF of patients with PD, MSA and controls. These substances are important for cell growth, and act as important modulators of a variety of ion channels, including glutamate NMDA and AMPA receptors. CSF total polyamine, N^1^acetyl-cadaverine, and cadaverine levels were increased both in PD and MSA, but PD patients showed higher CSF putrescine and lower CSF spermidine levels than MSA and controls, and MSA patients showed lower CSF N^1^acetylputrescine than PD and controls. CSF N^8^-acetylspermidine levels were higher in PD patients than in controls, and in MSA than in PD patients and controls.

Conclusions {#s2}
===========

A.  The majority of classical biochemical studies on neurotransmitter and related substances have described decreased CSF HVA, and normal NE, MHPG, ACh, AChE, glutamate, aspartate, and glycine levels in patients with PD. Results on CSF GABA and 5-HIAA levels are controversial. Many of these classical studies included patients with different types of Parkinsonism and had a limited number of patients and controls.

B.  Studies on the possible value of endogenous neurotoxins, oxidative stress markers, inflammatory and immunological markers, and growth and neurotrophic factors as biological markers of PD should be considered as inconclusive. The most consistent finding related with these issues is the possible role of CSF urate on the progression of the disease (Ascherio et al., [@B18]).

C.  Data regarding the role of CSF total *tau* and phospho*tau* as biological markers for PD are inconsistent. The most interesting findings are the possible relations of these markers with the progression of the disease (Zhang et al., [@B344]), and with the preservation of cognitive function in PD patients (Stewart et al., [@B283]).

D.  CSF α-synuclein levels have been found to be decreased in most, but not all, studies in PD patients compared with controls. This marker should be useful for the differential diagnosis between synucleopathies and other parkinsonian syndromes, but its usefulness to differentiate among synucleopathies (PD, PDD, DLBD, and MSA), remains to be elucidated.

E.  CSF Aβ1-42 levels could be considered as a useful marker of the presence of further cognitive decline in PD patients.

F.  CSF NFL protein levels should be useful for the differential diagnosis of PSP, MSA, CBD, and PDD from PD, but not to discriminate between PD and healthy controls.

Future approaches
=================

While possible biomarkers for PD in classical studies have been hypothesis-driven, attempts to develop effective procedures for the differential diagnosis of PD in its early stages have led to the performance of CSF multianalyte methods including systematic measurements of patterns of variation in proteins (proteomics) or small molecules (metabolomics). These methods have led to the identification of possible unexpected biomarkers of diseases involved in neurodegenerative processes. However, the results of these types of studies, which are briefly described below, are not clearly established and await replication.

Guo et al. ([@B109]), in a proteomic analysis of the CSF of PD patients and controls, found significantly higher CSF levels of apolipoprotein E, autotoxin, and some SOD1 isoforms, and lower levels of complement C~4~ when compared with controls, while Pigment epithelium-derived factor (PEDF or serpin F1) was not significantly increased, and complement C~3~ and haptoglobin were similar in PD patients and controls.

Zhang et al. ([@B345]) performed a proteomics-discovered multianalyte profile (MAP) in CSF on 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD, and concluded that the optimal MAP leading to the correct diagnosis was composed of the following proteins in order of contribution: tau, BDNF, IL-8, Aβ42, β2-microglobulin, vitamin D binding protein, apoA2, and apoE.

Maarouf et al. ([@B174]) analyzed ventricular CSF from PD and controls obtained in the immediate post-mortem period using a two-dimensional difference gel electrophoresis (2D-DIGE) coupled with mass spectrophotometry protein identification, and found differences between the 2 groups in 6 molecules: fibrinogen, transthyretin, apoE, clusterin, apoA1, and glutathione-S-transferase-Pi (GSTP).

Trupp et al. ([@B307]) reported a generally lower level of metabolites in PD as compared to controls, with a specific decrease in 3-hydroxyisovaleric acid, tryptophan, and creatinine, a significant decrease in the levels of Aβ-38 and Aβ-42, and an increase in soluble amyloid peptide precursor α (APPα) in CSF of patients.

Ideally, future studies should fulfill the following conditions: (a) a multicenter and prospective design; (b) inclusion of patients diagnosed with PD and other types of parkinsonism according to standardized criteria; (c) measurement of multiple potential biological markers in the CSF; (d) a very long-term follow-up period (till death as end-point), with assessment of both clinical features and serial determinations of the biological markers; and (e) final neuropathological confirmation by examination of the brains of patients at death (this is lacking in most of the studies published).
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